Cargando…

Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA Study

BACKGROUND AND AIMS: Progressive multifocal leukoencephalopathy [PML], a brain infection associated with anti-integrin drugs that inhibit lymphocyte translocation from bloodstream to tissue, can be fatal. Decreased central nervous system [CNS] immune surveillance leading to this infection has been r...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Haens, Geert, Vermeire, Séverine, Vogelsang, Harald, Allez, Matthieu, Desreumaux, Pierre, Van Gossum, Andre, Sandborn, William J, Baumgart, Daniel C, Ransohoff, Richard M, Comer, Gail M, Ahmad, Alaa, Cataldi, Fabio, Cheng, John, Clare, Robert, Gorelick, Kenneth J, Kaminski, Annamarie, Pradhan, Vivek, Rivers, Sunday, Sikpi, Matthew O, Zhang, Yanhua, Hassan-Zahraee, Mina, Reinisch, Walter, Stuve, Olaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881743/ https://www.ncbi.nlm.nih.gov/pubmed/28961770 http://dx.doi.org/10.1093/ecco-jcc/jjx128

Ejemplares similares

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
por: Sandborn, William J, et al.
Publicado: (2018)

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
por: Saruta, Masayuki, et al.
Publicado: (2020)

Physiologically relevant binding affinity quantification of monoclonal antibody PF‐00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation
por: Wang, Mengmeng, et al.
Publicado: (2016)

Tosca
por: Puccini, Giacomo, 1858-1924
Publicado: (1993)

Tosca
por: Puccini, Giacomo, 1858-1924
Publicado: (1990)

Tosca /
por: Puccini, Giacomo, 1858-1924
Publicado: (1991)

Tosca
Publicado: (1986)

Tosca
por: Puccini, Giacomo, 1858-1924
Publicado: (1991)

Tosca
por: Puccini, Giacomo, 1858-1924
Publicado: (1992)

Tosca : melodramma in 3 atti
por: Puccini, Giacomo, 1858-1924
Publicado: (1954)

The TOSCA-GEANT Interface Tools
por: Klioukhine, V I
Publicado: (1998)

Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study
por: D’Haens, Geert R, et al.
Publicado: (2021)

TOP: a prototype for the TOSCA experiment
por: CERN. Geneva. SPS-PS Experiments Committee
Publicado: (1998)

Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis
por: Jharap, B., et al.
Publicado: (2015)

TOSCA-based orchestration of complex clusters at the IaaS level
por: Caballer, M, et al.
Publicado: (2017)

Magnetic Studies on QDC53 Using the TOSCA Code
por: Harold, M R
Publicado: (1985)

Policy-Based Holistic Application Management with BPMN and TOSCA
por: Calcaterra, Domenico, et al.
Publicado: (2023)

The treatment of severe child aggression (TOSCA) study: Design challenges
por: Farmer, Cristan A, et al.
Publicado: (2011)

Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study
por: Nabbout, Rima, et al.
Publicado: (2018)

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
por: Vermeire, Séverine, et al.
Publicado: (2021)

Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn’s Disease: Results from the EXTEND Trial
por: Reinisch, Walter, et al.
Publicado: (2017)

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study
por: Sandborn, William J, et al.
Publicado: (2021)

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study
por: Steere, Boyd, et al.
Publicado: (2023)

Three dimensional TOSCA calculations on the TRIUMF second arm spectrometer magnet
por: Lobb, D E
Publicado: (1990)

The Tosca Registry: An Ongoing, Observational, Multicenter Registry for Chronic Heart Failure
por: Arcopinto, M, et al.
Publicado: (2016)

Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II
por: Reinisch, Walter, et al.
Publicado: (2021)

Calculation of the TileCal magnetic forces using 3D Tosca model
por: Nessi, Marzio, et al.
Publicado: (1998)

Calculation of the TileCal magnetic forces using 3D Tosca model
por: Morozov, N A, et al.
Publicado: (1997)

Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies
por: Mukherjee, Arnab, et al.
Publicado: (2022)

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Next-Generation Therapeutics for IBD
por: Löwenberg, Mark, et al.
Publicado: (2015)

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
por: Panaccione, Remo, et al.
Publicado: (2018)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study
por: de Vries, Petrus J., et al.
Publicado: (2018)

Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study
por: Jansen, Anna C., et al.
Publicado: (2020)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients
por: Kingswood, John C., et al.
Publicado: (2017)

Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry
por: Marques, Ruben, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fc1eoddqk8vr81afsfhdi7ovoa